Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4768
Source ID: NCT03338803
Associated Drug: Linagliptin
Title: Real World Glycemic Effectiveness of Linagliptin
Acronym:
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT03338803/results
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Linagliptin
Outcome Measures: Primary: Change in Glycosylated Hemoglobin (HbA1c) Across Age Categories, Change in HbA1c among adults with type 2 diabetes mellitus (T2DM) within the 60 to 180 days following initiation of linagliptin across pre-defined age categories (40 to 54 years, 40 to 54 years, 65 to 74 years and 75+ years). Change in HbA1c, was calculated for each patient by subtracting the patient's last (most recent) HbA1c value during the pre-index period (including the index date) from the patient's last (most recent) HbA1c value 60 to 180 days after the index date., Baseline and 60 to 180 days|Change in Glycosylated Hemoglobin (HbA1c) Across Renal Function Categories, Change in HbA1c among adults with type 2 diabetes mellitus (T2DM) within the 60 to 180 days following initiation of linagliptin across pre-defined renal function categories. Change in HbA1c, was calculated for each patient by subtracting the patient's last (most recent) HbA1c value during the pre-index period (including the index date) from the patient's last (most recent) HbA1c value 60 to 180 days after the index date. Renal function categories were presented based on patients with a pre-index estimated glomerular filtration rate (eGFR) value (eGFR\<30, eGFR 30 to 44, eGFR 45 to 59, eGFR 60 to 89, eGFR ≥ 90 milliliter/ minute/1.73 meter\^2 and eGFR not available)., Baseline and 60 to 180 days | Secondary: Percentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across the Pre-defined Age Categories, Percentage of adults with T2DM who achieve HbA1c \< 7.0% within the 60 to 180 days following initiation of linagliptin across pre-defined age categories (40 to 54 years, 40 to 54 years, 65 to 74 years and 75+ years)., 60 to 180 days|Percentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across Renal Function Categories, Percentage of adults with T2DM who achieve HbA1c \< 7.0% within the 60 to 180 days following initiation of linagliptin across pre-defined renal function categories. Renal function categories were presented based on patients with a pre-index estimated glomerular filtration rate (eGFR) value (eGFR\<30, eGFR 30 to 44, eGFR 45 to 59, eGFR 60 to 89, eGFR ≥ 90 milliliter/ minute /1.73 meter\^2 and eGFR not available)., 60 to 180 days
Sponsor/Collaborators: Sponsor: Boehringer Ingelheim | Collaborators: Eli Lilly and Company
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 11001
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2017-11-21
Completion Date: 2018-02-02
Results First Posted: 2019-05-06
Last Update Posted: 2019-05-06
Locations: Optum, Eden Prairie, Minnesota, 55344, United States
URL: https://clinicaltrials.gov/show/NCT03338803